BCR and neoplasm: We first analyzed the differences between tumor immunogenicity and immune activation-related biomarkers (TMB, TCR richness, and BCR richness) among subtypes and found that TMB, antigen-specific T-cell receptor (TCR) richness, and B-cell receptor (BCR) richness, which determines the robustness of the anti-tumor response, were enriched in C2 compared with C3 IS (Figure 6A).